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Abstract 
The population vaccination effectiveness (PVE) is defined as the 
fraction of disease cases prevented by a vaccination campaign. We 
use occupancy urn models to estimate the PVE, and compare results 
for leaky, ali-or-nothing and VEl (vaccine efficacy for infectiousness) 
vaccines using data of a measles outbreak and San Francisco current 
AIDS epidemic. This latter motivated by the current development of 
HIV vaccines of the VEl type. When applying our method to predict 
PVE for the San Francisco AIDS epidemic, our model predicts that 
PVE will be relatively low, even if the fraction of vaccinated and the 
efficacy of the vaccine are high. 
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1 INTRODUCTION 
Human interest with epidemics of infectious diseases and their associated 
human mortality has a long history. However, the scientific study of epi-
demiology of infectious diseases started with the development of the 'germ 
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theory of disease' [l]. The research on this field has produced many discov-
eries and developments including the creation of vaccines. 
An evaluation of the performance of a vaccination program at the pop-
ulation level should at least involve a measure of the direct protective effect 
of the vaccine on every person, which has been measured by the so called 
vaccine efficacy (VE) [5-9• ll-l3]. It also must incorporate its indirect effects 
such as those associated with herd immunity, that is, the reduction in dis-
ease probability (for vaccinees and non-vaccinees) resulting from the reduc-
tion in the proportion of infectious individuals[!, 51. An index that considers 
these two factors is the Population Vaccination Effectiveness (PVE), which 
is ususally defined as 
lob 
PVE = 1- E[l] (1) 
where lob denotes the observed attack rate in the population and E[l] 
denotes the corresponding expected attack rate (in the same population) in 
the absence of vaccination. [5]. PVE measures the fraction of disease cases 
prevented by a vaccination programme, and thus, it can help public health 
authorities in the evaluation of the efficacy of a public health campaign. 
The above formula, as we will show, it can be used to predict the PVE of a 
vaccination campaign as a function of the VE and the vaccinated fraction. 
The fraction of cases prevented by a vaccination campaign have been con-
sidered before by Struchiner et al, Halloran and Struchiner,(see Haber[5l).In 
the same article, Haber[5l (1997) coins the term 'population vaccination 
effectiveness' to describe the effect of a vaccination campaign at the popula-
tion level. The main difficulty in the estimation of PVE in formula (1) arises 
from the term E[l], the expected value of the number of infectives without 
vaccination campaign. It may be possible to estimate E[l] from data col-
lected prior to vaccination, or from observations on a similar unvaccinated 
population isolated from the study population. Even if such estimates exist, 
however, they would be unreliable in many cases(see Haber 1997). 
In this work, we use occupancy urn models to estimate E[l] and apply 
the approach based on this method to data from a measles outbreak in Scott 
City, Kansas. We also apply this method to predict the PVE for the current 
AIDS epidemic in San Francisco, California. We discuss the effect of f, the 
fraction of the population vaccinated, and the effect of the VE on the PVE 
for three different types of vaccines, that can be distinguished according 
to their action[2, 7• 11l.They are:all-or-nothing vaccines, leaky vaccines and 
VEI(vaccine efficacy for infectiousness) vaccines. *All-or-nothing vaccines 
2 
'• 
afford complete protection to a fraction of the vaccinated people. Leaky 
vaccines reduce the probability of infection per contact for a vaccinated per-
son to some (nonzero) value. We consider a vaccine under development 
whose purpose is to break the chain of infection of HIV (Human Immun-
odeficiency Virus). Its mode of action is called VEl because its goal is to 
reduce the infectiousness of an individual !21. 
An important question arises regarding these vaccines: can we ever be 
able to stop the AIDS epidemic by means of these type of vaccines? When 
is it too late to implement them? We will analyze how successful the use of 
the VEl on the AIDS epidemic using data from the current AIDS epidemic 
in San Francisco could be. 
2 METHODOLOGY 
We present the basic framework_ on occupancy urn models that is required 
to understand our approach. Consider placing n balls in N urns, where 
N is assumed to be large. It is also assumed that every urn can hold an 
unlimited number of balls and that the probability that a ball falls in urn 
i, i = 1, 2, 3, ... , N, is N-1. That is, the placements of balls in urns are 
independent events. 
Under mild conditions, the distribution of the number of empty urns is 
well modeled by a Poisson distribution with parameter 
e = Ne-n/N (2) 
(Von Mises, 1939)!101. The conditions are, that N and n tend to infin-
ity in such away that e remains bounded. Thus, the expected number of 
occupied urns is give by 
(3) 
A variation in this type of model is the "leaky urn model". Under 
this model, once an urn receives a ball, it may escape inmediately with 
probability {3, and the number of empty urns after attempting placing n 
balls tends also to a Poisson distribution with parameter!101 e where 
0 = Ne-n/3/N (4) 
We use the following analogy to describe the role of a vaccine in reducing 
an epidemic: N in (2-4) corresponds to the total number of susceptible 
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individuals in the population at the beginning of an epidemic. The number 
of occupied urns at the end of an epidemic corresponds to the total number 
of infected individuals, and thus, empty urns correspond to those individuals 
who remain susceptible. The role of n, the number of placed balls, is the 
total number of threats of infection. These threats may or not may result 
in an infection depending on the urn (being previously empty or occupied). 
An individual may receive any number of threats but its infectiousness does 
not depend on the number of threats (balls) received. Our model simply 
classifies individuals in two types, useful particulary when one looks infected 
(occupied) or susceptible (empty). 
This analogy is at the final size of an epidemic, which is achieved when 
the last ball placed falls in an occupied urn. Since n, the number of threats 
of infection is proportional to the number of infected, n that is n = c I, 
where c is the number of threats of infection that every infected produces(c 
plays the role of the basic reproductive number or Rt1l). Then the expected 
number of susceptible( empty urns) is given by 
E[SJ = N- E[Ij = N e-J1{) I/N (5) 
where S is the number of empty urns and I is the number of occupied 
urns provided that each newly occupied urn produces itself (and throws) Ro 
balls. 
We can construct an estimate of Ro by solving for Ro in (5) and equating 
1\ 
E[I] to the observed number of occupied urns U, that is, an estimate Ro for 
Ro is given by 
1\ N ( u) Ro= -ULog 1- N (6) 
For a fixed (known) values of Ro, it is possible to estimate E[I] by solving 
for Ro this in (5). Numerical methods are required because there is no closed 
form for E[I]. 
2.1 ALL-OR-NOTHING VACCINES 
Suppose that at the beginning of the epidemic, there is only one infected 
individual (urn) and suppose that this urn disperses its Ro balls randomly 
among N urns. Those urns that receive at least one ball become 'infected' 
and will disperse their respective Ro balls among the remaining urns. When 
a fraction f of the population is vaccinated with an ali-or-nothing vaccine 
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with V E = 1- {3, that is ,with a fraction {3 of those vaccinated not protected 
by the vaccine, then the immune fraction equals f(1- {3). The rest of the 
individuals remain susceptible. In terms of the urn model, this would be 
equivalent to have some of the urns covered, in the sense that they can 
receive balls, but without becoming infected. 
As it can be seen in (1), it is required to estimate E[J], but first we need 
to estimate Ro. We need to gather information on Ro with a population that 
has been already vaccinated. We still can use (4), but we need to correct 
for the number of 'susceptible' urns. In the following, N1, is the number 
of vaccinated individuals and No = N- N1. The number of susceptible 
individuals (or available urns) is then No+ N1{3. 
A correction for the number dropped balls at the end of the epidemic is 
given by 
(7) 
This last expression corrects for the fraction of balls that fall into sus-
ceptible urns. If I is the number of infected urns at the end of the epidemic, 
then from (5) we have that 
E[J] = (No + N1{3) ( 1 - e- No:Nif3) , 
which simplifies to 
E[J] =(No+ N1{3) 1- e- N . ( .&!.!.) (8) 
Solving for Ro, we have 
A N ( fobs ) 
Ro= -y log No + N1{3 (9) 
where lobs, is the observed number of infected individuals during an 
epidemic. This estimate of Ro can be subsituted in (8) and then solve for I 
which becomes in fact the estimate of E[J] in (1) yielding 
E[J] = N ( 1- e-RoE[IJ/N) 




2.2 LEAKY VACCINES 
This type of vaccine reduces the susceptibility of infection from 1 to /3 for all 
the vaccinated individuals, that is, every time the individual has a contact 
with the infectious agent, its probability of infection is reduced from 1 to 
/3. Observe that the probability that a person do not become infected in k 
contacts is (1-f])k. Most of the last cosiderations are maintained. Neverthe-
less, for a leaky vaccine the number of infected at the end of the epidemic 
is similar to the number of occupied urns in the 'leaky urn model', where in 
every contact of infection, the ball has a probability /3 to stay in the urn, and 
1-/3 to escape. Notice that the contact by itself do not produces infection, 
unless the ball remains in the urn. 
We first consider the case of partial vaccination before the epidemic. In 
this case a fraction f of the population is vaccinated, and we define N 1 = N f, 
as the number of vaccinated individuals. We can consider that there are two 
type of urns, type 0 and type 1 for the non vaccinated and the vaccinated 
respectively. Thus the expected number of susceptible individuals at the end 
of the epidemic is the sum of the susceptibles vaccinated and unvaccinated. 
Provided that the Poisson limit applies, we have 
.&!. E[susceptibles typeO] = N(1- f)e- N (11) 
and 
Roi/3 
E[susceptibles type1] = N f e- N (12) 
Hence 
E[susceptibles] = E[susceptibles type OJ + E[susceptibles type 1], 
.&!_ Rpi/3 
= N (1 - f) e- N + N fe- N , 
and from ( 5) we have that 
E[I] = N- N (1- f) e- N + N fe N ( .&!. §J.!!!. ) (13) 
Thus we can solve for Ro in (13) to provide an estimate of Ro, from 
where we can estimate PVE using (1). 
2.3 VEl TYPE VACCINES. 
An analogous urn model for VEl type of vaccine would be one in which 
every infected individual reduces the amount of balls it can throw, Ro to a 
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fraction Ro a, 0 < a < 1. Note that if a is very low aRo is very low and 
each individual is less infectious and the vaccine efficacy is VE=1-a. 
For this type of vaccine we will study two cases: partial vaccination 
before the epidemic and partial vaccination of susceptible individuals during 
the epidemic. 
Vaccination before the epidemic starts 
In the case of partial vaccination before the epidemic we assume that, 
at the beginning of the epidemic, there is only one infected individual, and 
that this individual (urn) disperses its Ro balls randomly. Those urns that 
receive at least one ball become infected and will in turn disperse aRo balls 
if they are vaccinated and Ro if they are not. At the end of an epidemic 
there will be infected individuals of two types: the type 0 for unvaccinated 
individuals (Io), and the type 1 for vaccinated individuals (h). Therefore 
the total of infected individuals is Io + h. From (2) we have 
(14) 
where the total number of balls dispersed no, will be a fraction of the 
total number of balls thrown, that is 
no= Ro (Io + ha) (1- f) (15) 
where Ro (Io + ha) is the total number of ball produced and (1- f) is 
the fraction that falls in the unvaccinated population. Hence 
E[Io] = (1 -f) N ( 1 - e- Ro(I~11 "'>) (16) 




E[Io + h] = N 1 - e- N ( Rp(Ip+J! o)) (18) 
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and from (18) we have the following estimate for Ro 
1\ -N ( Io +h) 
Ro= Io + Ira log 1 - N · (19) 
which can be used to obtain E[Io + h] for different values of f and a. 
Thus we obtain a predictor for the PVE. 
Vaccination during the epidemic starts 
If the vaccine is applied to a population that contains already infected 
individuals then we have to specify what kind of effect will the vaccine have in 
these infected (assumed infectious) individuals. In the worst case scenario, 
the vaccine will have no effect on them and thus the PVE would depend 
mainly on what happens to the new cases. This particular case is relevant 
to AIDS, in which that the epidemics can be driven by infections would 
generated in the primary infectious phase of the disease and therefore, a 
potential VEl vaccine will have little effect on those that have been infected 
for a long time. To simplify our model, we assume that the vaccine has no 
effect on already infected individuals and study the evolution of an epidemic 
on the remaining susceptible individuals. 
The infected population is composed of both old and newly infected in-
dividuals. Let the number of already infected individuals Iini· This implies 
that Iini have Ro balls at the time the vaccination campaign starts. Thus, 
the Iini individuals will continue to disperse their Ro balls amongst the sus-
ceptible population. Suppose that a fraction f of the susceptible population 
S is vaccinated hence, if N1 is the number of vaccinated individuals then 
at the end of an epidemic, there will be Io infected unvaccinated individu-
als and h infected vaccinated individuals. Therefore, the total number of 
susceptibles becoming infected at the end of an epidemic is Io + h and the 
expected number of infected among the non-vaccinated individuals is 
(20) 
where the total number no of balls dispersed is a fraction of the total 
number of balls thrown by all infected during the epidemic, that is 
(1- f) s 
no= Ro Uini + Io +Ira) N (21) 
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where Ro (Iini + Io + ha) denotes the total number of threats of infec-
tion (balls), ~ is the fraction of these balls that fall into susceptibles and 
(1 -f) the fraction that falls into the unvaccinated. Since 
no Ro(Iini+lo+ha)(1-f)S 
No (1- f) S N (22) 
we have that 
(23) 
Similarly, we find that 
(24) 
If Ro,or an estimate of Ro is known, then we can use the last two expres-
sions to estimate E[Io + h] for different fraction of vaccinated and different 
a's, and then use these estimates to estimate PVE. 
3 DISCUSSION AND RESULTS. 
3.1 COMPARING ALL-OR-NOTHING AND LEAKY VAC-
CINES. 
Differentiation between leaky and ali-or-nothing vaccines is difficult. As we 
have seen, the PVE depends on the mode of action of the vaccine and thus 
if this process is unknown, then we can only try to estimate the PVE under 
both modes of action. For the Scott City measles outbreak data[6], we found 
similar results for both aU-or-nothing and leaky vaccines. In figures 1 and 2, 
it can be seen that there is a critical value of approximately 0.62, at which 
an increase in the fraction of vaccinated does not increase significatively the 
PVE. It can also be seen that there is an approximate linear relationship 
with the accinated fraction for both kinds of vaccines when f is below the 
critical value. Figure 1 shows the results for the effect of f on the PVE for 
the preschool group whereas Figure 2 is for elementary school population. 
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PVE vs. f 
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Figure 1. Graphs of PVE vs. vaccinated fraction (f) for preschool children 
effected by measles epidemic with a vaccine efficacy, V E = 0.85, No=l19, 




PVE vs. f 
all-nolhing 
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Figure 2. Graphs of PVE vs. vaccinated fraction ( f ) for elementary 
school children effected by measles epidemic with a vaccine efficacy, 
VE=0.927, No=76, N1=459, Iab=35, for all-nothing vaccine and leaky 
vaccine respectively. 
3.2 ANALYSIS OF THE AIDS EPIDEMIC IN SAN FRAN-
CISCO: EFFECT OF VEl ON PVE. 
The goal of this section is to analyze the effect of a potential VEI vaccine 
applied to the population in San Francisco. The population size is N = 
10 
1,003,9981151, and the number of currently infected is Iini = 7,9211141. At 
this point, the efficacy of such a vaccine is unknown, and the vaccinated 
fraction plays an important role, specially since we have to consider that a 
lot of people may not be easily persuaded to take the vaccine12l. 
To run our model, we need initial estimates of Ro. In our study we take 
Ro = 2,6,8, and 12, whereas the VE of the potential VEl is from 0 to 1 
at increments of 0.05. The fraction of vaccinated also varies from 0 to 1. 
Figures 12-15 show our results. 
It can be seen that for Ro values as low as 2, it is possible to obtain PVE's 
close to 1 if the VE is close to 1 and all the susceptibles are vaccinated, 
whereas for Ro values as high as 12, the campaign will reach a PVE value 
smaller than 0.2 for a VE of 0.80 if all the susceptibles are vaccinated. If 
the vaccinated fraction is 0.80 (a rather optimistic fraction) no VEl vaccine 
will reach a PVE of 0.2. If the vaccinated fraction is less than 60 percent, 
then the campaign will be practicaly ineffective. 
~§~~~f 
0.2 0.4 0.6 0.8 1 
Figure 3. Effect off on PVE for an VEl vaccine, while varying efficacy 1-a. 
Case Ro = 2 
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Figure 4. Effect off on PVE for an VEl vaccine, while varying efficacy 1-a. 
Case Ro = 6 
1\E w f 
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0.2 0.4 0.6 0.8 1 
Figure 5. Effect off on PVE for an VEl vaccine, while varying efficacy 1-a. 
Case Ro = 8 
0. 
0. 
-~-- -- f 
0.2 0.4 0.6 0.8 1 
Figure 6. Effect off on PVE for an VEl vaccine, while varying efficacy 1-a. 
Case Ro = 12 
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3.3 ANALYSIS OF THE AIDS EPIDEMIC IN SAN FRAN-
CISCO: COMPARING PONTENTIAL ALL-OR-NOTHING, 
LEAKY, AND VEl VACCINES. 
Figures 7 and 8 show the comparison between the predicted PVE for the 
three kinds of vaccines: aU-or-nothing, leaky and VEl for a=0.2 and a=0.4 
respectively, with Ro=8.We can see that the PVE of the aU-or-nothing vac-
cine is far above of the PVE of the leaky vaccine for the same fraction of 
vaccinated, and that the PVE of the VEl vaccine is below the PVE of a 
leaky vaccine. A interesting result arises: even if the VE of the VEl vaccine 
is relatively high (around 0.8) and the fraction of vaccinated is optimistically 
high (90 %), the predicted PVE is below 0.4. 





f 0.2 0.4 0.6 0.8 1 
Figure 7. Comparison between aU-or-nothing, leaky and VEl vaccines. 
Ro=8 , a=0.2. 
13 
. . 
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Figure 8. Comparison between aU-or-nothing, leaky and VEl vaccines. 
Ro=8 , a=0.4. 
4 CONCLUSIONS 
Estimation of PVE is a valuable tool to assess the quality of previous vac-
cination programmes, or in the prediction of the effects of a disease in a 
population under a vaccine campaign. 
Occupancy urn models provide a simple way to derive PVE estimate for 
different types of vaccines. It is also an ideal framework to develop confidence 
intervals, which could in turn be used to assess the level of confidence of the 
predictions. More research needs to be done regarding the ditributional 
properties of the PVE. 
For the specific measles outbreak that we considered, it is seen that in 
order to obtain a valuable vaccination programme, it is needed to vaccinate 
most of the population and to have an efficient vaccine, both implemented 
vaccines showed similar impact on the PVE. 
One important conclusion derived from our model is that more research 
is required towards the development of alternative all/nothing or leaky vac-
cines that could halt the AIDS epidemic, since according to our estimates, 
the predicted population vaccination effectiveness of a VEl type vaccine 
(even assuming a high VE and a high fraction of vaccinated), is low. This 
is especially disturbing since it is expected that it would be difficult to con-
vince people to be vaccinated with a vaccine that does not confer them 
immunity -total o partial-, but instead protects other people from being 
infected.l2l Besides is also covenient to consider the sector of the population 
14 
that is vaccinated, since people in certain groups are more exposed to be-
come infected. Moreover, it should be considered that vaccination may cause 
changes in the behaviour of vaccinated, a topic already considered elsewhere, 
thus, vaccinated people could increase their contact rate and thus the effects 
of vaccination could be reversed. 
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